Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$4.9 million.

  • Adma Biologics' Change in Account Payables fell 40135.97% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 6291.81%. This contributed to the annual value of $4.1 million for FY2024, which is 810.11% up from last year.
  • As of Q3 2025, Adma Biologics' Change in Account Payables stood at -$4.9 million, which was down 40135.97% from $9.3 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Change in Account Payables peaked at $13.8 million during Q3 2022, and registered a low of -$12.0 million during Q4 2022.
  • Over the past 5 years, Adma Biologics' median Change in Account Payables value was $142000.0 (recorded in 2025), while the average stood at $772526.3.
  • Per our database at Business Quant, Adma Biologics' Change in Account Payables soared by 1628000.0% in 2024 and then tumbled by 40135.97% in 2025.
  • Over the past 5 years, Adma Biologics' Change in Account Payables (Quarter) stood at -$4.9 million in 2021, then crashed by 146.61% to -$12.0 million in 2022, then skyrocketed by 141.73% to $5.0 million in 2023, then dropped by 21.07% to $3.9 million in 2024, then plummeted by 223.69% to -$4.9 million in 2025.
  • Its Change in Account Payables stands at -$4.9 million for Q3 2025, versus $9.3 million for Q2 2025 and $142000.0 for Q1 2025.